Drug Type Small molecule drug |
Synonyms KME 0584 |
Target |
Mechanism IRAK1 antagonists(Interleukin-1 receptor-associated kinase 1 antagonists), IRAK4 inhibitors(Interleukin-1 receptor-associated kinase 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization Kurome Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | IND Approval | US | Kurome Therapeutics, Inc.Startup | 15 Feb 2024 |
High Risk Myelodysplastic Syndrome | IND Approval | US | Kurome Therapeutics, Inc.Startup | 15 Feb 2024 |